TICKERNERD
Menu
VTVTVTVTHealthcare · Biotechnology

VTVT Stock Forecast: vTv Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$24
+2.04% on the day

The 6 Wall Street analysts covering vTv Therapeutics, Inc. hold a median 12-month price target of $57 — +137.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$93.1M
Ticker Nerd rank
84/ 100
Median analyst target
$57
Analysts covering
6
Revenue$0.0
Operating income−$13.9M
Net income−$13.1M
Free cash flow−$11.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
−21.4%
YTD
−39.9%
1Y
−3.6%
From 52W high
−43.7%
From 52W low
+2.3%
$24
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores vTv Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
84/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Quality
86
Volatility
74
Size
74
Value
74
Revisions
70
Momentum
70
Issuance
35
Accruals
11

Growth (96): Sales and profits are climbing, and climbing faster than before.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VTVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26VTVTHigh $67Median $57Low $42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $42Median $57High $67

The green dot is the last close — the median target sits +137.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
14 Oct 2026BTIGReiteratesBuy$57
6 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $42
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
16 July 2026BTIGMaintainsBuy$49 → $57
16 July 2026BTIGMaintainsBuy—
12 Mar 2026Evercore ISI GroupInitiatesOutperform—
11 Mar 2026BTIGReiteratesBuy—
27 Jan 2026BTIGMaintainsBuy—
23 Jan 2026Roth CapitalInitiatesBuy—
5 Jan 2026TD CowenInitiatesBuy—
19 Dec 2025HC Wainwright & Co.MaintainsBuy—
19 Nov 2025BTIGInitiatesBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
9 Apr 2025HC Wainwright & Co.InitiatesBuy—
9 Dec 2024Alliance Global PartnersInitiatesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy$6.00
17 Aug 2022Northland Capital MarketsMaintainsOutperform$1.50 → $2.00
18 Feb 2022Cantor FitzgeraldInitiatesOverweight—
10 Feb 2020H.C. WainwrightReiteratesBuy—
10 Feb 2020HC Wainwright & Co.ReiteratesBuy$5.00 → $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VTVT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VTVT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, vTv Therapeutics, Inc. returned −3.6% against +12.9% for the S&P 500, dividends included.

VTVT vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26VTVTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VTVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

vTv Therapeutics, Inc. (VTVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.4×

Cheaper than 92% of US stocks

Price / sales
2.5×

Cheaper than 45% of US stocks

Price / book
3.7×

Cheaper than 25% of US stocks

EV / EBITDA
−22.3×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−25.1%

Higher than 20% of US stocks

Net margin
−12.9%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−15.8%

Higher than 33% of US stocks

Return on assets
−10.1%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

vTv Therapeutics, Inc. (VTVT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • vTv Therapeutics, Inc. has a market value of $93.1M and an enterprise value of $206.0M.

  • Revenue in the twelve months to 30 June 2026: $36.8M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$6.4M, a −17.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.06.

  • Free cash flow in the twelve months to 30 June 2026: −$16.8M.

  • Shares outstanding: 3.9M.

  • Trailing P/E: −7.4×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • vTv Therapeutics, Inc. employs 26 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

VTVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VTVTvTv Therapeutics, Inc.$93.1M84
ICCCImmuCell Corp.$93.1M93
NRXPNRX Pharmaceuticals, Inc.$94.0M13
MISTMilestone Pharmaceuticals, Inc.$94.5M19
VANIVivani Medical, Inc.$94.7M46
UNCYUnicycive Therapeutics, Inc.$95.9M43
EQEquillium, Inc.$89.1M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own vTv Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTVT news & analysis

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems

GlobeNewsWire · 27 Oct 2026positive

vTv Therapeutics announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study of cadisegliatin in people with type 1 diabetes using hybrid closed-loop insulin delivery systems. The study is intended to inform the design and conduct of future Phase 3 research in this population.

Why it matters — The trial milestone advances evaluation of cadisegliatin as an investigational oral adjunct to insulin for type 1 diabetes.

vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia

MarketBeat · 21 Oct 2026neutral

vTv Therapeutics held a virtual key opinion leader event covering the continuing burden of hypoglycemia in type 1 diabetes, patient and physician market-research findings, and the development program for investigational oral therapy cadisegliatin.

Why it matters — The event provides VTVT watchers an update on the rationale and development program for cadisegliatin.

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

GlobeNewsWire · 7 Oct 2026positive

vTv Therapeutics announced that the FDA granted orphan drug designation to HPPD for sickle cell disease. The company said the milestone supports partnering discussions while it continues to prioritize its lead late-stage type 1 diabetes program, cadisegliatin.

Why it matters — The designation may support the company's efforts to pursue a partner for HPPD as it focuses on cadisegliatin.

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

GlobeNewsWire · 6 Oct 2026neutral

vTv Therapeutics announced a virtual key opinion leader event on hypoglycemia in type 1 diabetes and its cadisegliatin Phase 3 program, scheduled for October 20, 2026, at 2:30 p.m. ET.

Why it matters — The event will provide VTVT watchers an opportunity to hear discussion of hypoglycemia in type 1 diabetes and the company’s cadisegliatin Phase 3 program.

FAQ

Frequently asked questions about VTVT stock

What is the VTVT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering vTv Therapeutics, Inc. have a median 12-month price target of $57, with estimates ranging from $42 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VTVT stock a buy right now?

Of the 6 analysts covering vTv Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks vTv Therapeutics, Inc. 84 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTVT?

As at 3 Nov 2026, vTv Therapeutics, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will VTVT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +137.2% from the last close, and Ticker Nerd's factor model ranks vTv Therapeutics, Inc. 84 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VTVT stock forecast for 2030?

No analyst covering vTv Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $67 over the next 12 months.

How has VTVT stock performed over the past year?

vTv Therapeutics, Inc. returned -3.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does vTv Therapeutics, Inc. do?

vTv Therapeutics Inc. Class A Common Stock represents equity in vTv Therapeutics, a late-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes and other chronic diseases.

What is the latest news on VTVT?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems". vTv Therapeutics announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study of cadisegliatin in people with type 1 diabetes using hybrid closed-loop insulin delivery systems. The study is intended to inform the design and conduct of future Phase 3 research in this population.

Company

About vTv Therapeutics, Inc.

vTv Therapeutics Inc. Class A Common Stock represents equity in vTv Therapeutics, a late-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes and other chronic diseases. The company’s current pipeline centers on treatments designed to address metabolic and inflammatory conditions, with particular emphasis on diabetes-related programs and other areas of unmet medical need. vTv Therapeutics works primarily through the discovery and clinical development of drug candidates intended for oral administration, a format that supports convenient long-term use in chronic disease care. Its business is concentrated on advancing proprietary therapeutic programs rather than commercial product sales, making the company a development-stage participant in the biotechnology sector. vTv Therapeutics is headquartered in High Point, North Carolina, and its Class A common stock is its primary public equity class.

CEO Mr. Paul J. Sekhri · 26 employees · United States · https://vtvtherapeutics.com